Metformin, as the AMP-activated protein kinase (AMPK) activator, is the most widely used for overweight patients with T2D, and it also has favorable effects on NAFLD by reducing insulin resistance and hepatic triglyceride accumulation [10]. The gene discussed is PRKAA1; the disease is Insulin resistance.